STUDY

Protopic worked as well as a mid-strength steroid for eczema

“Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis.” Reitamo S et al. Journal of Allergy and Clinical Immunology. March 2002

Reitamo S et al. · Journal of Allergy and Clinical Immunology · March 2002

Randomized controlled trialEczemaProtopicHydrocortisone
The finding

In a 3-week trial of 570 adults with moderate to severe eczema, 0.1% tacrolimus ointment worked about as well as a mid-to-strong steroid ointment (hydrocortisone butyrate). The weaker 0.03% tacrolimus did not match them.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. A random process decided who got which ointment, and neither the patients nor the doctors knew which one they had.
At a glance

Who was studied and for how long

People
570
About 190 in each group
Length
3 weeks
Applied twice a day
Condition
Moderate to severe eczema (atopic dermatitis)
Adults
Compared
Tacrolimus 0.03% and 0.1% vs hydrocortisone butyrate 0.1%
Ointments
How often
Twice daily
All groups
What they did

How the study worked

570 peoplemoderate to severe eczemaRANDOMSPLIT0.03% tacrolimus193 people · twice daily0.1% tacrolimus191 people · twice daily0.1% hydrocortisone butyrate186 people · twice dailyMEASURED ATWeek 3by doctors570 peoplemoderate to severe eczemaRANDOMSPLIT0.03% tacrolimus193 people · twice daily0.1% tacrolimus191 people · twice daily0.1% hydrocortisonebutyrate186 people · twice dailyMEASURED ATWeek 3by doctors
1. Split at random570 adults with moderate to severe eczema were randomly put in one of three groups.
2. Same routineEach group used its ointment twice a day on all affected skin for 3 weeks.
3. ScoreThe main result was the modified eczema area and severity index (mEASI), measured against the starting level.
What they found

The results

0.03% tacrolimus0.1% tacrolimus0.1% hydrocortisone butyrate

Eczema score as a share of the starting level

Median mEASI over the 3 weeks, as a percent of where it started. Lower is better.

Tacrolimus 0.03%
47.0%
Tacrolimus 0.1%
36.5%
Hydrocortisone butyrate
36.1%
The 0.1% tacrolimus and the hydrocortisone butyrate ended up almost the same, with no statistically significant difference between them. The 0.03% tacrolimus scored higher, meaning less improvement.
How much to trust it

Strengths and limits

Strengths

  • Randomized and double-blind
  • Large: 570 adults
  • Compared tacrolimus with an ointment in the same class people actually use

Limits

  • Only 3 weeks, so it cannot show long-term safety or skin thinning
  • Adults only; the results do not apply to children
  • Tests one steroid, not every steroid strength
  • The summary shows medians, not every p-value
High confidence. A large, double-blind randomized trial. It covers 3 weeks in adults only.
What it means for you

The takeaway

About equal

For adult eczema, 0.1% tacrolimus ointment worked about as well as a mid-to-strong steroid ointment over 3 weeks.

Tacrolimus is a steroid-free option, often used on the face, eyelids, and skin folds. Ask your dermatologist which fits your skin and how long to use it.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

Atopic dermatitis

The most common type of eczema. It causes dry, itchy, inflamed skin.

mEASI

Modified Eczema Area and Severity Index. A score for how much skin is affected and how red, thick, and scratched it is.

Calcineurin inhibitor

A non-steroid medicine class that calms the immune response in the skin. Tacrolimus is one.

Double-blind

Neither the people in the study nor the doctors measuring results knew who got which treatment. This keeps hopes and expectations from coloring the results.

Original source

Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schoepf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T, European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547–555.

PMID 11898005